Argenx Se (ARGX) Assets (2015 - 2026)
Argenx Se's (ARGX) quarterly Assets came in at $10.0 billion in Q2 2026, up 39.81% YoY from $7.2 billion in Q2 2025, and up 15.54% on a QoQ basis from $8.7 billion in Q4 2025.
Argenx Se (ARGX) Assets (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Assets data on file, last reported at $10.0 billion in Q2 2026.
- Quarterly Assets rose 39.81% year-over-year to $10.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $10.0 billion (up 39.81% YoY) and the FY2025 annual result came in at $8.7 billion, up 39.99% from the prior year.
- Assets grew to $10.0 billion in Q2 2026, from $8.7 billion in the prior quarter.
- In the past five years, Assets ranged from a high of $10.0 billion in Q2 2026 to a low of $3.1 billion in Q4 2022.
- A 5-year average of $5.7 billion and a median of $4.8 billion in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2023 — Assets decreased 1.71% — and 2024, when it surged 50.18%.
- Tracing ARGX's Assets over 5 years: stood at $3.1 billion in 2022, then surged by 44.93% to $4.5 billion in 2023, then soared by 36.55% to $6.2 billion in 2024, then surged by 39.99% to $8.7 billion in 2025, then rose by 15.54% to $10.0 billion in 2026.
- The last three Assets figures came in at $10.0 billion (Q2 2026), $8.7 billion (Q4 2025), and $7.2 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.03 Bn |
| Dec 31, 2025 | 8.68 Bn |
| Jun 30, 2025 | 7.18 Bn |
| Dec 31, 2024 | 6.20 Bn |
| Jun 30, 2024 | 4.80 Bn |
| Dec 31, 2023 | 4.54 Bn |
| Jun 30, 2023 | 3.19 Bn |
| Dec 31, 2022 | 3.13 Bn |
| Jun 30, 2022 | 3.25 Bn |
| Dec 31, 2021 | 2.85 Bn |
| Jun 30, 2021 | 3.21 Bn |
| Dec 31, 2020 | 2.21 Bn |
| Jun 30, 2020 | 2.23 Bn |
| Dec 31, 2019 | 1.59 Bn |
| Jun 30, 2019 | 1.13 Bn |
| Dec 31, 2018 | 660.25 Mn |
| Jun 30, 2018 | 429.66 Mn |
| Dec 31, 2017 | 436.72 Mn |
| Jun 30, 2017 | 203.95 Mn |
| Dec 31, 2016 | 114.20 Mn |